标题
Recent progress concerning CpG DNA and its use as a vaccine adjuvant
作者
关键词
-
出版物
Expert Review of Vaccines
Volume 13, Issue 2, Pages 299-312
出版商
Informa UK Limited
发表日期
2013-12-18
DOI
10.1586/14760584.2014.863715
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of CpG Oligonucleotides on Vaccine-Induced B Cell Memory
- (2014) D. Tross et al. JOURNAL OF IMMUNOLOGY
- The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma
- (2013) Kai-Michael Beeh et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
- (2013) Wim H.J. Kruit et al. JOURNAL OF CLINICAL ONCOLOGY
- -Defensin 2 and 3 Promote the Uptake of Self or CpG DNA, Enhance IFN- Production by Human Plasmacytoid Dendritic Cells, and Promote Inflammation
- (2013) P. Tewary et al. JOURNAL OF IMMUNOLOGY
- Alginate-coated chitosan nanogel capacity to modulate the effect of TLR ligands on blood dendritic cells
- (2013) Thomas Démoulins et al. Nanomedicine-Nanotechnology Biology and Medicine
- Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine
- (2013) Renee Kim Kuan et al. VACCINE
- Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers
- (2013) Robert J. Hopkins et al. VACCINE
- The potential of 1018 ISS adjuvant in hepatitis B vaccines
- (2013) Nelson F Eng et al. Human Vaccines & Immunotherapeutics
- Therapeutic Administration of a Synthetic CpG Oligodeoxynucleotide Triggers Formation of Anti-CpG Antibodies
- (2012) J. Karbach et al. CANCER RESEARCH
- Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+T-cell responses in melanoma patients
- (2012) Simone M. Goldinger et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Intratumoral Injection of CpG Oligonucleotides Induces the Differentiation and Reduces the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells
- (2012) Y. Shirota et al. JOURNAL OF IMMUNOLOGY
- Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
- (2012) Erika Hamilton et al. Journal of Translational Medicine
- A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
- (2011) C. Manegold et al. ANNALS OF ONCOLOGY
- In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
- (2011) Y. H. Kim et al. BLOOD
- CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity
- (2011) Hidekazu Shirota et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study
- (2011) L. Klimek et al. CLINICAL AND EXPERIMENTAL ALLERGY
- CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
- (2011) C. Zoglmeier et al. CLINICAL CANCER RESEARCH
- Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy
- (2011) Curtis Cooper et al. Expert Review of Vaccines
- Transmembrane Mutations in Toll-like Receptor 9 Bypass the Requirement for Ectodomain Proteolysis and Induce Fatal Inflammation
- (2011) Maria L. Mouchess et al. IMMUNITY
- Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
- (2011) Vera Hirsh et al. JOURNAL OF CLINICAL ONCOLOGY
- Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase
- (2011) Sarah E. Ewald et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Suppressive Tumor Microenvironment: A Challenge in Cancer Immunotherapy
- (2011) Elizabeth A. Vasievich et al. MOLECULAR PHARMACEUTICS
- Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909
- (2011) Christopher J. A. Duncan et al. PLoS One
- Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers
- (2011) Dianna Rynkiewicz et al. VACCINE
- Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naive Prostate Cancer Patients
- (2010) J. Karbach et al. CLINICAL CANCER RESEARCH
- Intranasal Vaccinations with the trans-Sialidase Antigen plus CpG Adjuvant Induce Mucosal Immunity Protective against Conjunctival Trypanosoma cruzi Challenges
- (2010) O. K. Giddings et al. INFECTION AND IMMUNITY
- Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine?
- (2010) Emmanuel Lorne et al. INTENSIVE CARE MEDICINE
- Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice
- (2010) Qing Zhu et al. JOURNAL OF CLINICAL INVESTIGATION
- In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
- (2010) Joshua D. Brody et al. JOURNAL OF CLINICAL ONCOLOGY
- Prophylactic Administration of Bacterially Derived Immunomodulators Improves the Outcome of Influenza Virus Infection in a Murine Model
- (2010) E. B. Norton et al. JOURNAL OF VIROLOGY
- Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins
- (2010) N Lycke et al. Mucosal Immunology
- Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN
- (2010) Mohsen Tafaghodi et al. PARASITOLOGY RESEARCH
- Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP142-C1/Alhydrogel with and without CPG 7909 in Malaria Naïve Adults
- (2010) Ruth D. Ellis et al. PLoS One
- Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
- (2009) Jörg Vollmer et al. ADVANCED DRUG DELIVERY REVIEWS
- BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation
- (2009) J. Eckl-Dorna et al. BLOOD
- Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial
- (2009) G. Senti et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Critical Role for Asparagine Endopeptidase in Endocytic Toll-like Receptor Signaling in Dendritic Cells
- (2009) Fernando E. Sepulveda et al. IMMUNITY
- Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
- (2009) S. Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Vaccination With a Recombinant Protein Encoding the Tumor-specific Antigen NY-ESO-1 Elicits an A2/157-165-specific CTL Repertoire Structurally Distinct and of Reduced Tumor Reactivity Than That Elicited by Spontaneous Immune Responses to NY-ESO-1-expressing Tumors
- (2009) Gilles Bioley et al. JOURNAL OF IMMUNOTHERAPY
- Global changes in gene expression and synergistic interactions induced by TLR9 and TLR3
- (2009) Debra Tross et al. MOLECULAR IMMUNOLOGY
- A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel® with CPG 7909, using two different formulations and dosing intervals
- (2009) Ruth D. Ellis et al. VACCINE
- A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel®+CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults
- (2009) Issaka Sagara et al. VACCINE
- Paired Toll-like Receptor Agonists Enhance Vaccine Therapy through Induction of Interleukin-12
- (2008) R. Zheng et al. CANCER RESEARCH
- CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans
- (2008) W. N. Haining et al. CLINICAL CANCER RESEARCH
- Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients
- (2008) B. G. Molenkamp et al. CLINICAL CANCER RESEARCH
- Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles
- (2008) Olga Borges et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Christian Manegold et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma
- (2008) Maja A. Hofmann et al. JOURNAL OF IMMUNOTHERAPY
- Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients
- (2008) Julien Fourcade et al. JOURNAL OF IMMUNOTHERAPY
- The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor
- (2008) Sarah E. Ewald et al. NATURE
- Dynavax trial halted
- (2008) Laura DeFrancesco NATURE BIOTECHNOLOGY
- Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9
- (2008) Boyoun Park et al. NATURE IMMUNOLOGY
- Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
- (2008) Gregory E. D. Mullen et al. PLoS One
- The Adjuvant Effect of CpG Oligodeoxynucleotide Linked to the Non-Toxic B Subunit of Cholera Toxin for Induction of Immunity Against H. pylori in Mice
- (2008) J. Nyström-Asklin et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Toll-like receptor 9 in murine lupus: More friend than foe!
- (2007) Philipp Yu et al. IMMUNOBIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started